Patent ID: 8906857
Filing Date: 2014-12-09
Classification: C07K,G01N

Abstract:
1. A method of treating a critically ill human patient admitted to an intensive care unit (ICU) comprising: determining the concentration in nmol/l of a pro-adrenomedullin (pro-ADM) molecule and/or one or more physiologically occurring fragments thereof using a plasma sample from the patient in an in vitro selective immunodiagnostic assay recognizing a physiologically occurring fragment that is not the mature ADM, determining the concentration in nmol/l of a pro-endothelin (pro-END) molecule and/or one or more physiologically occurring fragments thereof using a plasma sample from the patient in an in vitro selective immunodiagnostic assay recognizing a physiologically occurring fragment that is not the mature END, wherein the immunodiagnostic assays use combinations of antibodies comprising antibodies produced against peptides having the amino acid sequences according to SEQ ID NO: 2 or 3 for pro-ADM and SEQ ID NO: 6 or 7 for pro-END, calculating the ratio of the pro-ADM concentration to the pro-END concentration, and when the concentration of pro-ADM is >8 nmol/l and the ratio of the pro-ADM concentration to the pro-END concentration is above 90, administering vasoactive endothelin in an amount sufficient to reduce the ratio of pro-ADM concentration to the pro-END concentration to below 90.